Comorbidities in Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes
- Registration Number
- NCT05874141
- Lead Sponsor
- New Valley University
- Brief Summary
Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today
- Detailed Description
All-cause mortality rates have declined substantially in several high-income countries, including England.
A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.
Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.
Many studies have primarily focused on identifying multimorbidity patterns in the general population.
The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 288
- Patients with type 2 diabetes.
- Patients with type 1 diabetes.
- Patients with secondary diabetes.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Number of participants with hypertension At time of inclusion in the study Number of participants with thyroid disorder At time of inclusion in the study Number of participants with Liver disease At time of inclusion in the study Number of participants with Coronary heart disease At time of inclusion in the study Number of participants with Infections At time of inclusion in the study Number of participants with dyslipidemia At time of inclusion in the study Number of participants with Diabetic kidney disease At time of inclusion in the study Number of participants with Stroke At time of inclusion in the study Number of participants with Peripheral arterial disease At time of inclusion in the study Number of participants with Diabetic eye disease At time of inclusion in the study Number of participants with Peripheral neuropathy At time of inclusion in the study Number of participants with Cancer At time of inclusion in the study
- Secondary Outcome Measures
Name Time Method Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity At time of inclusion in the study Correlate the presence of each co-morbidity with the extent of diabetes control At time of inclusion in the study
Trial Locations
- Locations (1)
New Valley University
🇪🇬Kharga Oasis, Egypt
New Valley University🇪🇬Kharga Oasis, EgyptAsmaa N Hussein, MDContact01065161752asmaanady_1010@med.nvu.edu.eg